Clinical Data completes NDA submission for vilazodone Clinical Data.

Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. THE BUSINESS expects that the NDA submission, if accepted, will be subject to a standard review.S. Reed, M.D., Executive Vice President and Chief Medical Officer of Clinical Data. In both of these eight-week trials, the efficacy of vilazodone was substantiated as proven by its superiority to placebo, with statistically significant results for the primary and multiple secondary endpoints. Results from efficacy measures within an uncontrolled long-term security study were in keeping with these findings. Typically, these adverse reactions occurred early in treatment and did not result in discontinuation of treatment with vilazodone. Overall, vilazodone has been shown to have a good safety profile and to be well tolerated in a data source of nearly 2,900 patients treated for up to 52 weeks..Beike was released its AABB certificate in January 2012. Dr. Shengqin Ye, President of Beike, commented, We are really pleased to have already been granted this accreditation. With this, Beike provides once again demonstrated a committed action to advanced learning, continuous improvement and technology to sustain optimum quality level and safety. Additionally, the ongoing company optimized its it platform and software program systems, adding a sophisticated bar code management program, real-time monitoring features, and a sophisticated enterprise source planning program to its call middle.

Other Posts From Category "gear":

Related Posts